Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine

Mayumi Ono, Naoyuki Kawahara, Daisuke Goto, Yukihiro Wakabayashi, Shin Ushiro, Shigeo Yoshida, Hiroto Izumi, Michihiko Kuwano, Yasufumi Sato

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Irsogladine used clinically as an anti-gastric ulcer agent, at 10-6- 10-4 M, inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer or glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histological analysis showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

Original languageEnglish
Pages (from-to)1512-1516
Number of pages5
JournalCancer Research
Volume56
Issue number7
Publication statusPublished - Apr 1 1996

Fingerprint

irsogladine
Anti-Ulcer Agents
Gastrointestinal Agents
Stomach Ulcer
Glioma
Growth
Neoplasms
Cell Proliferation
Angiogenesis Inhibitors
Liver Neoplasms
Morphogenesis
Hepatocytes
Endothelial Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ono, M., Kawahara, N., Goto, D., Wakabayashi, Y., Ushiro, S., Yoshida, S., ... Sato, Y. (1996). Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Research, 56(7), 1512-1516.

Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. / Ono, Mayumi; Kawahara, Naoyuki; Goto, Daisuke; Wakabayashi, Yukihiro; Ushiro, Shin; Yoshida, Shigeo; Izumi, Hiroto; Kuwano, Michihiko; Sato, Yasufumi.

In: Cancer Research, Vol. 56, No. 7, 01.04.1996, p. 1512-1516.

Research output: Contribution to journalArticle

Ono, M, Kawahara, N, Goto, D, Wakabayashi, Y, Ushiro, S, Yoshida, S, Izumi, H, Kuwano, M & Sato, Y 1996, 'Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine', Cancer Research, vol. 56, no. 7, pp. 1512-1516.
Ono M, Kawahara N, Goto D, Wakabayashi Y, Ushiro S, Yoshida S et al. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Research. 1996 Apr 1;56(7):1512-1516.
Ono, Mayumi ; Kawahara, Naoyuki ; Goto, Daisuke ; Wakabayashi, Yukihiro ; Ushiro, Shin ; Yoshida, Shigeo ; Izumi, Hiroto ; Kuwano, Michihiko ; Sato, Yasufumi. / Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. In: Cancer Research. 1996 ; Vol. 56, No. 7. pp. 1512-1516.
@article{4464b1399d614bb8b4d87c7a0e740bfc,
title = "Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine",
abstract = "Irsogladine used clinically as an anti-gastric ulcer agent, at 10-6- 10-4 M, inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer or glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histological analysis showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.",
author = "Mayumi Ono and Naoyuki Kawahara and Daisuke Goto and Yukihiro Wakabayashi and Shin Ushiro and Shigeo Yoshida and Hiroto Izumi and Michihiko Kuwano and Yasufumi Sato",
year = "1996",
month = "4",
day = "1",
language = "English",
volume = "56",
pages = "1512--1516",
journal = "Cancer Research",
issn = "0008-5472",
number = "7",

}

TY - JOUR

T1 - Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine

AU - Ono, Mayumi

AU - Kawahara, Naoyuki

AU - Goto, Daisuke

AU - Wakabayashi, Yukihiro

AU - Ushiro, Shin

AU - Yoshida, Shigeo

AU - Izumi, Hiroto

AU - Kuwano, Michihiko

AU - Sato, Yasufumi

PY - 1996/4/1

Y1 - 1996/4/1

N2 - Irsogladine used clinically as an anti-gastric ulcer agent, at 10-6- 10-4 M, inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer or glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histological analysis showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

AB - Irsogladine used clinically as an anti-gastric ulcer agent, at 10-6- 10-4 M, inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer or glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histological analysis showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0029864384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029864384&partnerID=8YFLogxK

M3 - Article

C2 - 8603395

AN - SCOPUS:0029864384

VL - 56

SP - 1512

EP - 1516

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -